Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s Disease
26 sept. 2024 08h00 HE
|
Acumen Pharmaceuticals, Inc.
Agreement builds upon a successful collaboration supporting the manufacture of sabirnetug (ACU193) drug substance (DS) for clinical studies in Alzheimer’s diseaseExtension to provide drug product (DP)...
Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024
25 sept. 2024 16h00 HE
|
Acumen Pharmaceuticals, Inc.
NEWTON, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic...
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investor Conference
03 sept. 2024 16h00 HE
|
Acumen Pharmaceuticals, Inc.
NEWTON, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble...
Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Highlights
13 août 2024 07h00 HE
|
Acumen Pharmaceuticals, Inc.
Actively enrolling subjects in ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease Dosed the first subject in a Phase 1 study to support...
Acumen Pharmaceuticals to Report Second Quarter Results on August 13, 2024
06 août 2024 16h00 HE
|
Acumen Pharmaceuticals, Inc.
NEWTON, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic...
Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer’s Disease
29 juil. 2024 07h00 HE
|
Acumen Pharmaceuticals, Inc.
NEWTON, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid...
Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
28 juil. 2024 07h30 HE
|
Acumen Pharmaceuticals, Inc.
NEWTON, Mass., July 28, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble...
Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
11 juil. 2024 08h00 HE
|
Acumen Pharmaceuticals, Inc.
NEWTON, Mass., July 11, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble...
Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights
14 mai 2024 07h00 HE
|
Acumen Pharmaceuticals, Inc.
Announced initiation of ALTITUDE-AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer’s disease, in May 2024Initiation of a Phase 1 study to support a...
Acumen Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
13 mai 2024 16h00 HE
|
Acumen Pharmaceuticals, Inc.
CHARLOTTESVILLE, Va., May 13, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic...